title: Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug-drug interaction.
authors.forename: Isabel
authors.initials: I
authors.lastname: Spriet
authors.forename: Veerle
authors.initials: V
authors.lastname: Grootaert
authors.forename: Geert
authors.initials: G
authors.lastname: Meyfroidt
authors.forename: Yves
authors.initials: Y
authors.lastname: Debaveye
authors.forename: Ludo
authors.initials: L
authors.lastname: Willems
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics; D001682:Biological Availability; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D065692:Cytochrome P-450 CYP3A Inhibitors; D004347:Drug Interactions; D016903:Drug Monitoring; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics; D016031:Liver Transplantation / Q000276:immunology; D008297:Male; D008875:Middle Aged; D055732:Pulmonary Aspergillosis / Q000188:drug therapy / Q000382:microbiology; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics; D014230:Triazoles / Q000008:administration & dosage* / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics; D065819:Voriconazole
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000935:Antifungal Agents; D065692:Cytochrome P-450 CYP3A Inhibitors; D007166:Immunosuppressive Agents; D011743:Pyrimidines; D014230:Triazoles; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D065819:Voriconazole; D016559:Tacrolimus